GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroGen Inc (STU:1FG) » Definitions » Institutional Ownership

FibroGen (STU:1FG) Institutional Ownership : 33.26% (As of Jun. 20, 2024)


View and export this data going back to 2015. Start your Free Trial

What is FibroGen Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, FibroGen's institutional ownership is 33.26%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, FibroGen's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, FibroGen's Float Percentage Of Total Shares Outstanding is 84.78%.


FibroGen Institutional Ownership Historical Data

The historical data trend for FibroGen's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroGen Institutional Ownership Chart

FibroGen Historical Data

The historical data trend for FibroGen can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 45.08 40.19 36.64 36.96 34.60 34.46 34.40 33.51 33.34 33.26

FibroGen Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


FibroGen (STU:1FG) Business Description

Traded in Other Exchanges
Address
409 Illinois Street, San Francisco, CA, USA, 94158
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

FibroGen (STU:1FG) Headlines

No Headlines